630 related articles for article (PubMed ID: 22828645)
1. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
[TBL] [Abstract][Full Text] [Related]
3. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
[TBL] [Abstract][Full Text] [Related]
4. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM
Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288
[TBL] [Abstract][Full Text] [Related]
5. Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers.
Booy R; Nolan T; Reynolds G; Richmond P; Nissen M; Marshall H; Stoney T; Van Der Wielen M; Kolhe D; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):1379-84. PubMed ID: 26372451
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
[TBL] [Abstract][Full Text] [Related]
7. Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age.
Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Heron L; Lambert S; Caubet M; Mesaros N; Boutriau D
Pediatr Infect Dis J; 2011 Apr; 30(4):340-2. PubMed ID: 21068692
[TBL] [Abstract][Full Text] [Related]
8. Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
Tejedor JC; Brzostek J; Konior R; Grunert D; Kolhe D; Baine Y; Van Der Wielen M
Clin Vaccine Immunol; 2016 Jul; 23(7):555-63. PubMed ID: 27145999
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
[TBL] [Abstract][Full Text] [Related]
10. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
[TBL] [Abstract][Full Text] [Related]
11. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
Khatami A; Snape MD; Wysocki J; John TM; Westcar S; Mesaros N; Peddiraju K; Boutriau D; Yu LM; Pollard AJ
Pediatr Infect Dis J; 2012 Oct; 31(10):1069-73. PubMed ID: 22673139
[TBL] [Abstract][Full Text] [Related]
12. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
[TBL] [Abstract][Full Text] [Related]
13. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants.
Nolan T; Lambert S; Roberton D; Marshall H; Richmond P; Streeton C; Poolman J; Boutriau D
Vaccine; 2007 Dec; 25(51):8487-99. PubMed ID: 17996996
[TBL] [Abstract][Full Text] [Related]
14. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
15. A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.
Pace D; Snape M; Westcar S; Oluwalana C; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
Arch Dis Child; 2008 Nov; 93(11):963-70. PubMed ID: 18463125
[TBL] [Abstract][Full Text] [Related]
16. A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
Pace D; Snape M; Westcar S; Hamaluba M; Yu LM; Begg N; Wysocki J; Czajka H; Maechler G; Boutriau D; Pollard AJ
Pediatr Infect Dis J; 2007 Nov; 26(11):1057-9. PubMed ID: 17984816
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
Nolan T; Booy R; Marshall HS; Richmond P; Nissen M; Ziegler JB; Baine Y; Traskine M; Jastorff A; Van der Wielen M
Pediatr Infect Dis J; 2019 Jun; 38(6):643-650. PubMed ID: 31116180
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.
Schmitt HJ; Maechler G; Habermehl P; Knuf M; Saenger R; Begg N; Boutriau D
Clin Vaccine Immunol; 2007 Apr; 14(4):426-34. PubMed ID: 17287313
[TBL] [Abstract][Full Text] [Related]
19. Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.
Pace D; Khatami A; Attard-Montalto S; Voysey M; Finn A; Faust SN; Heath PT; Borrow R; Snape MD; Pollard AJ
Vaccine; 2016 Dec; 34(50):6350-6357. PubMed ID: 28029540
[TBL] [Abstract][Full Text] [Related]
20. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months.
Díez-Domingo J; Cantarino MV; Torrentí JM; Sansano MI; Rosich AJ; Merino AH; de Miguel AG; González JB; Marcos MD;
Pediatr Infect Dis J; 2010 Feb; 29(2):148-52. PubMed ID: 19927040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
